Brighter News For Varlitinib As Results In Tough Cancer Type Encourage ASLAN
Executive Summary
Following a major setback in another indication earlier this year, ASLAN’s lead asset is now seen as a potential new option for second-line use in biliary tract cancer following promising new data from a Chinese trial.